Journal Papers




Dasyam N, Sharples KJ, Barrow C, Huang Y, Bauer E , Mester B, Wood CE, Authier‑Hall A, Dzhelali M, Ostapowicz T, Kumar R, Lowe J, Maxwell A, Burn OK,. Williams GM, Carley SE, Caygill G, Jones J, Chan STS, Hinder VA, Macapagal J, McCusker M, Weinkove R, Brimble MA, Painter GF, Findlay MP, Dunbar PR, Gasser O, Hermans IF.  A randomised controlled trial of long NY‑ESO‑1 peptide‑pulsed autologous dendritic cells with or without alpha‑galactosylceramide in high‑risk melanoma. Cancer Immunology, Immunotherapy. 2023


Sharples K, Vear NK, Porter-Steele J, Anderson D, Moeke-Maxwell T, Laing BB, Young L, Bailey TG, Benge S, Huang Y, Crowley E, Day R, Cartwright R, Findlay M, Porter D, Kuper M, Campbell I, McCarthy AL. Protocol of trans-Tasman feasibility randomised controlled trial of the Younger Women’s Wellness After Breast Cancer (YWWACP) lifestyle intervention. Pilot and Feasibility Studies. 2022;8 Article number 165


Jeong SH, Chavani O, Burns K, Porter D, Findlay M, Helsby N. Severe 5‑fluorouracil‑associated gastrointestinal toxicity unexplained by dihydropyrimidine dehydrogenase deficiency and renal impairment: Should we be investigating other elimination pathways to assess the risk of 5‑fluorouracil toxicity? European Journal of Drug Metabolism and Pharmacokinetics. 2021; 46, 817-820

Helsby N, Burns K, Findlay M, Porter D, Strother M. Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. New Zealand Medical Journal. 2021;134(1545):106-114

Helsby N, Yong M, Burns K, Findlay M, Porter D.  Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.  Cancer Chemotherapy and Pharmacology. 2021;

Burns KE, Chavani O, Jeong SH, Duley JA, Porter D, Findlay, M, Strother RM, Helsby N. Comparison of a thymine challenge test and endogenous uracil-dihydrouracl levels for assessment of fluoropyrimidine toxicity risk. Cancer Chemother Pharmacology. 2021;


Vasista A, Stockler MR, Martin A, Lawrence NJ, Keily BE. Communicating prognostic information: what do oncologists think patients with incurable cancer should be told? International Medicine Journal. 2020;

Cebon JS, Gore M, Thompson JF, David ID, McArthur GA, Walpole E, Smithers M, …Findlay MPN… et al.  Results of a randomized, double- blind phase II clinical trial of NY- ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high- risk resected melanoma. Journal for ImmunoTherapy of Cancer 2020;


Helsby NA, Duley J, Burns KE, Bonnet C, Jeong SH, Brenman E, Barlow P, Sharples K, Porter D, Findlay M.  A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. British Journal of Clinical Pharmacology. 2019;1-10.

So YJ, Jameson M, Newton V, O’Donnell A, Jeffrey M, Jackson C, Tuck A, Gregory K, North R, Anderson, M, Sharples K, Findlay M, Wilson MK. Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand.  New Zealand Medical Journal. 2019;132(1498):10-31

Henare KL, Parker KE, Wihongi H, Blenkiron C, Jansen R, Reid P, Findlay MP, Lawrence B, Hudson M, Print CG.  Mapping a route to Indigenous engagement in cancer genomic research. The Lancet Oncology. 2019;20 (6):e327-e335.


Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, Robb T, Yeong ML, Kramer N, James S, Black M, Fan V, Poonawala N, Yap P, Coats E, Woodhouse B, Ramsaroop R, Yozu M, Robinson B, Henare K, Koea J, Johnston P, Carroll R, Connor S, Morrin H, Elston M, Jackson C, Reid P, Windsor J, MacCormick A, Babor R, Bartlett A, Damianovich D, Knowlton N, Grimmond S, Findlay M, Print C. Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. NPJ Genomics Medicine. 2018 Jul 20;3:18. doi: 10.1038/s41525-018-0058-3. PMID: 30062048; PMCID: PMC6054670.

Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, Gebski V, Van Buskirk M, Zhao H, van Hazel G, SIRFLOX and FOXFIRE Global trial investigators. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies, Clinical Colorectal Cancer 2018; doi: 10.1016/j.clcc.2018.06.001.

Woodhouse B, Robb TJ, Hearn JI, Houseman PS, Hayward G, Miller R, Restall AP, Findlay M, Lawrence B, Print CG, Parker K, Blenkiron C. Merkel cell polymavirus is uncommon in New Zealand Merkel cell carcinomas. British Journal Dermatology 2018;179(5):1197-1198.

Sharples, K, Firth M, Hinder V, Hill A, Jeffery M, Sarfati D, Brown C, Atmore C, Lawrenson R, Reid P, Derrett S, Macapagal J, Keating J, Secker A, De Groot C, Jackson C, Findlay M. The New Zealand PIPER Project: colorectal cancer survival according to rurality, ethnicity and socioeconomic deprivation—results from a retrospective cohort study. New Zealand Medical Journal 2018; 131 (No 1476):24-39

Corter AL, Broom R, Porter D, Harvey V, Findlay M. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer. Psychooncology. 2018 May 18. doi: 10.1002/pon.4771. [Epub ahead of print]

Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, Mester B, Dzhelali M, Caygill G, Jones J, Hayman CM, Hinder VA, Macapagal J, McCusker M, Weinkove R, Painter GF, Brimble MA, Findlay MP, Dunbar PR, Hermans IF. A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunol Immunother 2018; 67(2):285-98.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, et al. Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in second-line RAS wild-type metastatic colorectal cancer. Clin Cancer Res 2018; 24(10):2276-84.


Wilson M, Mak W, Firth M, Deva S, Findlay M. Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care. N Z Med J 2017; 130(1460):63-72.

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18(9):1159-71.

Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O’Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017; 24(8):2252-8.

Robb T, Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, Yeong ML, Kramer N, Findlay M, Print C. Homing in on precise diagnoses: the power of combining multi-layered genomic and histopathological analysis in pancreatic cancer. AGTA Conference 2017; Poster #34.

Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG. Multimodal assessment of estrogen receptor mRNA profiles to quantify estrogen pathway activity in breast tumors. Clin Breast Cancer 2017; 17(2):139-53.

Sharma N, Gibbs P, Van Hazel G, Heinemann V, Ricke J, Findlay M, Gebski V, Moschandreas J, Virdee PS, Dutton P, Taieb J, PeetersM, Tait P, Boardman P, Lewington V, Al-Nahhas A, Wasan HS, Sharma RS. The FOXFIRE/SIRFLOX/FOXFIRE-Global randomised studies of first-line selective internal radiation therapy for metastatic colorectal cancer. Abstract for EANM Annual Meeting 2017.

Sharma RA, Wasan HS, Van Hazel GA, Heinemann V, Sharma NK, Taieb J, Ricke J, Mills J, Tait NP, Boardman P, Peeters M, Findlay MPN, Virdee PS, Moschandreas J, Gebski V, Love S, Gray A, Gibbs P. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol 2017; 35(15_suppl):3507.

Wasan H, Sharma RA, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, et al. FOXFIRE-SIRFLOX-FOXFIRE Global Prospective Randomised Studies of First-Line Selective Internal Radiotherapy (SIRT) in Patients with Liver Metastases from Colorectal Cancer: KRAS Mutation and Tumour Site Analysis. Vol. 28, no. suppl_5, Oxford University Press, 2017, p. 615.

Wasan H, Van Hazel G, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, et al. O-027: Overall survival analysis of the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. Ann Oncol 2017; 28(S3):148.

Van Hazel G, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, Gibbs P, SIRFLOX and FOXFIRE-Global trial investigators; LBA-006 Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. Ann Oncol 2017; 28 (Suppl_3):mdx302.005.

Wasan H, Van Hazel G, Heinemann V, Sharma N, Taieb J, Ricke J, Peeters M, Findlay M, VirdeeP, et al. 146P Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line SIRT in patients with mCRC. Ann Oncol 2017; 28 (Suppl_10):mdx659.004.


Burns KE, Lo WY, Findlay MP, Sharples K, Laking G, Helsby NA. High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemother Pharmacol 2016; 77(1):195-204.

Van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016; 34(15):1723-31.

Gibbs P, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 34 (4_suppl):637.

Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke K, Peeters M, Gebski V, Van Buskirk M, Gibbs P. Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX study. Ann Oncol 2016; 27 (Suppl 2):ii19-20.

Heinemann V, Van Hazel GA, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX study: Novel approach to define depth of response (DpR) within a volumetric model in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2016; 34(15_suppl):3542.

Heinemann V, Van Hazel G, Sharma N, Findlay M, Ricke J, Peeters M, Gebski V, Van Buskirk M, Gibbs P. Evaluation of depth of response within a volumetric model in patients with metastatic colorectal cancer: results of the SIRFLOX study. Ann Oncol 2016; 27(2):118-128.

Firth MJ, Sharples KJ, Hinder VA, Macapagal J, Sarfati D, Derrett SL, Hill AG, Brown C, Reid PMJ, Lawrenson RA, Atmore C, Keating JP, Jeffery M, Secker AH, De Groot C, Jackson CGCA,  Findlay MPN. Methods of a national colorectal cancer cohort study: the PIPER Project. N Z Med J 2016; 129(1440):25-36.

Sharma N, Van Hazel G, Findlay M, Ricke J, Peeters M, Gebski V, Van Buskirk M, Gibbs P, Heinemann V. Using data from the SIRFLOX study to evaluate depth of response within a volumetric model in patients with metastatic colorectal cancer. J Vasc Interv Radiol 2017; 28 (2_Suppl):S160-1.


Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O’Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP. Everolimus and zoledronic acid in renal cell carcinoma patients with bone metastases; a randomized first-line phase II Trial. Clin Genitourin Cancer 2015; 13(1):50-8.

Perez D, Sharples KJ, Broom R, Jeffery M, Proctor J, Hinder V, Pollard S, Edwards J, Simpson A, Scott J, Benge S, Krissansen G, Geursen A, Palmano K, MacGibbon A, Keefe D, Findlay M. A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea. Support Care Cancer 2015; 23(11):3307-15.

Lawrence N, Hinder V, Murray M, Macapagal J, Thompson P, Sharples K, Findlay M. Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance? Asia Pac J Clin Oncol 2017; 13(2):e124-31; Epub 2015 Aug 6.

Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, Ancelet LR, Mester B, Sharples KJ, Findlay MP, Hamilton DA, Hermans IF. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J NeuroOncol 2015; 121(2): 319-29.

Prasad N, Sharples KJ, Murdoch DR, Crump J.A. Community prevalence of fever and relationship with malaria among infants and children in low-resource areas. Am J of Trop Med Hyg 2015; 93(1):178-80.

Jackson CGCA, Sharples K, Firth M, Hinder V, Jeffrey M, Keating J, Secker A, Derrett S, Atmore C, Bramley D, De Groot C, Stevens W, Sarfati D, Brown C, Hill A, Reid P, Lawrenson R, Findlay M. The PIPER Project: an internal examination of colorectal cancer management in New Zealand. Final report for the Health Research Council and the Ministry of Health, 7th April 2015. Available online Updated 2015. Accessed December 3, 2015.

Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M, Cunningham C. Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol 2015; 26(7):1325-32.

Wilson MK, Karakasis K, Oza AM: Discrepancies in drug approvals: A global dilemma. Cancer 2015; 121(18):3360-1.

Wilson MK, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al. Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol Oncol 2015; 138:285-91.

Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, et al. A phase II study of singleagent RO4929097, a gammasecretase inhibitor of Notch signalling, in patients with recurrent platinumresistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol 2015; 137(2):216-22.

Wilson MK, Karakasis K, Oza AM. Outcomes and endpoints in trials of cancer treatment: the past, present and future. Lancet Oncol 2015; 16(1):e32-42

Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, Kaye S, Parmar MK, Sydes MR, Tannock IF, Oza AM. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol 2015; 16(1):e43-52.

Castonguay V, Wilson MK, Diaz-Padilla I, Wang L, Oza AM. Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomised phase 3 studies in epithelial ovarian cancer.  Cancer 2015; 121(3):413-22.

Gibbs P, Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, Perez D, et al. Sirflox: Randomised phase III trial comparing first-line mFOLFOX6 +/- BEVACIZUMAB (BEV) versus mFOLFOX6 +/- BEV plus selective internal radiation therapy (SIRT) in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases, BEV treatment and site of first progression. Asia Pac J Clin Oncol 2015; 11:68-9.

Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, Perez D, et al. Sirflox: Randomised trial comparing first-line mFOLFOX6 +/- bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) +/- bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment. Ann Oncol 2015; 26 (Suppl_4):iv115.


Jackson C, Sharples K, Thompson PI, O’Donnell A, Robinson BA, Perez DJ, Adams J, Isaacs R, Deva S, Hinder VA, Findlay MP. Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. BMC Cancer 2014; 14:737.

Plunkett M, Murray M, Frizelle F, Teague L, Hinder V, Findlay M. Colorectal adenocarcinoma cancer in New Zealand in those under 25 years of age (1997-2007). ANZ J Surg 2014; 84(5):371-5.

Tiong J, Gray A, Jackson C, Thompson-Fawcett M, Schultz M. Audit of the association between length of time spent on diagnostic work-up and tumour stage in patients with symptomatic colon cancer. ANZ J Surg 2017; 87(3):138-42; Epub 2014 Aug 4.

Jackson C, Ehrenberg N, Frizelle F, Sarfati D, Balasingam A, Pearse M, Parry S, Print C, Findlay M, Bissett I. Rectal cancer: future directions and priorities for treatment, research and policy in New Zealand. N Z Med J 2014; 127(1395):63-72.

Jackson C, Robinson B, Findlay M. Cancer services to 2025 in New Zealand–investing in research-driven quality care. N Z Med J 2014; 127(1395):5-9.

Lheureux S, Wilson MK, Sinaei M, O’Malley M, Oza A. Non-target progression – the fine line between objectivity and subjectivity. Eur J Cancer 2014; 50(18):3271-2.

Lheureux S, Wilson M, Mackay HJ. Recent and current Phase II clinical trials in endometrial cancer: review of the state of the art. Expert Opin Investig Drugs 2014; 23(6): 773-92.

Wilson MK, Baguley BC, Wall C, Jameson MB, Findlay MP. Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol 2014; 10(1):22-37

Plunkett M, Murray M,  Frizelle F, Teague L, Hinder V, Findlay M. Colorectal Adenocarcinoma Cancer in New Zealand in those under 25 years of age (1997-2007). ANZ J Surg 2014; 84(5):371-5.


Jackson C, McCall J, Robinson B, Sharples K, Findlay M. Cancer trials in New Zealand—patients are not the problem. N Z Med J 2013; 126(1381):5-8.

Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL, Walther A, Jackson C, Stamp G, Webb J, Smith G, Gillbanks A, Swanton C. Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Invest New Drugs 2013; 31(5):1339-44.

Bidwell S, Simpson A, Sullivan R, Robinson B, Thomas W, Jackson C, Forgeson G, Jameson M, Clarke T. A workforce survey of New Zealand medical oncologists. N Z Med J 2013; 126(1371):45-53.

Rosario R, Wilson M, Cheng WT, Payne K, Cohen PA, Fong P, Shelling AN. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol 2013; 131(2):325-9.

Walton L, McNeill R, Stevens W, Murray M, Lewis C, Aitken D, Garrett J. Patient perceptions of barriers to the early diagnosis of lung cancer and advice for health service improvement. Fam Pract 2013; 30(4):436-44.

Harvey VJ, Sharples KJ, Isaacs RJ, Jameson MB, Jeffery GM, McLaren BR, …,Hinder, VA, Scott JN, Dzhelali MV, Findlay MP. A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II. Ann Oncol 2013; 24(7):1828-1834.


Cha R, Murray M, Thompson J, Wall CR, Hill A, Hulme-Moir M, Merrie A, Findlay M. Dietary patterns and information needs of colorectal cancer patients post-surgery in Auckland. N Z Med J 2012; 125(1356):38-46.

O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Master J, Kennedy-Smith A, Beaven T, Guilford PJ. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012; 188(3):741-7.

Pullar JM, Chisholm A, Jackson C. Dietary information for colorectal cancer survivors: an unmet need. N Z Med J 2012; 125(1356):27-37.


Murray M, Brown J, Hinder V, Merrie A, Hill A, Hulme-Moir M, Sharples K, Findlay M. The Colorectal cancer patients’ journey: the Auckland region. N Z Med J 2011; 124(1331):18-28.

Al-Mahrouqi H, Parkin L, Sharples K. Incidence of Stomach Cancer in Oman and the Other Gulf Cooperation Council Countries. Oman Med J 2011; 26(4):258-262.


Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, McKeage MJ. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer 2010; 10:451.

Han CH, Findlay MP. Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Intern Med J 2010; 40(2):153-9.

Leung E, Kannan N, Krissansen GW, Findlay MP, Baguley BC. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phosphor-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 2010; 9(9):717-24.

Corter A, Findlay MP, Broom R, Porter D, Petrie KJ. Breast Cancer, Illness Perceptions and Non-adherence to Aromatase Inhibitors. Int J Behav Med 2010; 17(Suppl 1):5

Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010; 2(2):85-106.

Dare T, Findlay M, Browett P, Amies K, Anderson S. Paternalism in practice: informing patients about expensive unsubsidised drugs. J Med Ethics 2010; 36(5):260-4.

Stevens W, Murray M. Barriers to the early diagnosis of lung cancer and recommended best practice solutions, with particular reference to Maori and Pacific peoples. Australas Epidemiol 2010; 17(3): 11-5.

Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma – clinical features and treatment outcomes from a 30-year experience. Ann Oncol 2010; 21(10):2061-8.


Jackson C. Cunningham D. Oliveira J.  Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:34-6


Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008; 19(2):212-22

Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, Gebski V, Stockler MR. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia Pac J Clin Oncol 2008; 4:55-67.

Ip V, McKeage MJ, Thompson, P, Damianovich D, Findlay M, Liu JJ. Platinum-specific detection and quantification of oxaliplatin and Pt (R,R-diaminocyclohexane) C12 in the blood plasma of colorectal cancer patients. J Anal At Spectrom 2008; 23(6):881-4.

Helsby NA, Lo WY, Sharples K, Riley G, Murray M, Spells K, Dzhelali M, Simpson A, Findlay M. CYP2C10 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008; 99(8):1251-5.

Jackson C, Cunningham D. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Eur J Cancer 2008; 44(5):652-62.

Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ. The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35(7):1323-9.

Furneaux CE, Marshall ES, Yeoh K, Monteith SJ, Mews PJ, Sansur CA, Oskouian RJ, Sharples KJ, Baguley BC. Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br J Cancer 2008; 99(10):1678-83.

Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 2008; 5:157-67.


Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Truskett P, Goldstein D, AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. ANZ J Surg2007; 77(4):247-52.

Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25(16):2198-204.

Findlay M, Sharples K, Riley G, Simpson A, Ackland S, Hall K, Isaacs R, Humm G, McKeage MJ. Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer. Asia Pac J Clin Oncol 2007; 3(2):99-105.

Parry S, Richardson A, Green T, Marshall B, Bissett I, Bloomfield A, Chadwick V, Cunningham C, Findlay M, Greer B, McMenamin J, Strid J, Robertson G, Teague C. Prospects for population colorectal cancer screening in New Zealand. N Z Med J 2007; 120(1258):U2633.

Jackson C, Cunningham D. A retrospective on inhibition of EGFR as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today’s patients. Clin Colorectal Cancer 2007; 7(Suppl 1):S8-15.

Jackson C, Starling N, Chau Y, Cunningham D. Pharmacotherapy in oesophagogastric cancer. Drugs 2007; 67(17): 2539-56.

Jackson C, Mochlinski K, Cunningham D. Defining standard of care and recognizing adjuvant therapeutic options in gastric cancer: neo-adjuvant chemotherapy vs. post-operative chemoradiotherapy. Oncology 2007; 21(9):1084-7.

Jackson C. The development of epidermal growth factor receptor-targeted therapies in gastrointestinal malignancies. Advances in Gastrointestinal Cancer 2007; 5(2):3-6.


Sullivan RN, Findlay MPN, Zalcberg J. Adjuvant and neoadjuvant therapy for gastric carcinoma: An evidence-based review. Am J Cancer 2006; 5(2):111-21.

Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P.  Hereditary diffuse gastric cancer: diagnosis and management. J Gastroentero Hepato 2006; 4(3):262-75.

Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V. Somatostatin receptor expression, tumour response and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006; 95(7):853-61.

Dunbar R, Findlay M, Stevens G. Melanoma control: few answers, many questions. N Z Med J 2006; 119(1242):U2172.


Loi S, Findlay M, Zalcberg J. Evidence-based adjuvant treatment of resectable pancreatic adenocarcinoma. Am J Cancer 2005; 4(3):159-68.

Nowak AK, Stockler MR, Chow PK, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer 2005; 103(7):1408-14.


Damjanovic D, Thompson P, Findlay M. Evidence-based update of chemotherapy options for metastatic colorectal cancer. ANZ J Surg 2004; 74(9):781-7.

Liu J, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, McKeage MJ. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol 2004; 31(10):677-82.

Christmas T, Findlay M. Lung cancer treatment in New Zealand: physician’s attitudes. N Z Med J 2004; 117(1196):U931.

Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004; 3:CD001024.

Koea J, MacCormack M, Findlay M, Ramsdorp R. Adeno-endocrine cancer of the gallbladder. ANZ J Surg 2004; 74(9):808-9.

Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40(10):1474-84.